Perioperative Clinical Results of Transcervical and Transhiatal Esophagectomy versus Thoracoscopic Esophagectomy in Patients with Esophageal Carcinoma: A Prospective, Randomized, Controlled Study (vol 15, pg 3393, 2022)

被引：0
|
作者：
Yin, Z.
Yang, R. M.
Jiang, Y. Q.
Chen, Q.
Cai, H. R.
机构：
来源：
INTERNATIONAL JOURNAL OF GENERAL MEDICINE | 2022年 / 15卷
关键词：
D O I：
10.2147/IJGM.S391500
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：7797 / 7798
页数：2
相关论文
共 44 条
  • [41] Early supplementation of parenteral nutrition is capable of improving quality of life, chemotherapy-related toxicity and body composition in patients with advanced colorectal carcinoma undergoing palliative treatment: results from a prospective, randomized clinical trial. (vol 12, pg e190, 2010)
    Hasenberg, T.
    Essenbreis, M.
    Herold, A.
    Post, S.
    Shang, E.
    COLORECTAL DISEASE, 2011, 13 (04) : 474 - 474
  • [42] Nimotuzumab plus concurrent chemo-radiotherapy versus chemo-radiotherapy in unresectable locally advanced esophageal squamous cell carcinoma (ESCC): Interim analysis from a prospective, randomized-controlled, double-blinded, multicenter, and phase III clinical trial (NXCEL1311 Study).
    Meng, Xue
    Zheng, Anping
    Wang, Jun
    Wang, Jianhua
    Li, Guang
    Zhu, Jun
    Ma, Hu
    Zhu, Xiaodong
    Shi, Anhui
    Dai, Chunhua
    Yan, Senxiang
    Wang, Buhai
    Qu, Zhongyu
    Han, Chun
    Sun, Xindong
    Ye, Ming
    Fan, Ruitai
    Huerxidan, Ni Yazi
    Wang, Xiaohong
    Yu, Jinming
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [43] Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: The NCIC Clinical Trials Group and AGITG CO.20 Trial (vol 31, pg 2477, 2013)
    Siu, L. L.
    Shapiro, J. D.
    Jonker, D. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (18) : 2124 - 2124
  • [44] Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial-a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial (vol 15, 160, 2014)
    Hill, Nathan R.
    Lasserson, Daniel
    Thompson, Ben
    Perera-Salazar, Rafael
    Wolstenholme, Jane
    Bower, Peter
    Blakeman, Thomas
    Fitzmaurice, David
    Little, Paul
    Feder, Gene
    Qureshi, Nadeem
    Taal, Maarten
    Townend, Jonathan
    Ferro, Charles
    McManus, Richard
    Hobbs, F. D. Richard
    TRIALS, 2022, 23 (01)
12345